Back to Search Start Over

Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma.

Authors :
Eckardt MA
Graham DS
Klingbeil KD
Lofftus SY
McCaw TR
Bailey MJ
Goldring CJ
Kendal JK
Kadera BE
Nelson SD
Dry SM
Kalbasi AK
Singh AS
Chmielowski B
Eilber FR
Eilber FC
Crompton JG
Source :
Annals of surgical oncology [Ann Surg Oncol] 2023 May; Vol. 30 (5), pp. 3097-3103. Date of Electronic Publication: 2022 Dec 29.
Publication Year :
2023

Abstract

Background: Surveillance imaging of patients with retroperitoneal liposarcoma (RP-LPS) after surgical resection is based on a projected risk of locoregional and distant recurrence. The duration of surveillance is not well defined because the natural history of RP-LPS after treatment is poorly understood. This study evaluated the long-term risk of recurrence and disease-specific survival (DSS) for a cohort of patients with at least 10 years of progression-free survival (10yr-PFS) from their primary resection.<br />Methods: The prospective University of California, Los Angeles (UCLA) Sarcoma Database identified RP-LPS patients with 10yr-PFS after initial resection. The patients in the 10yr-PFS cohort were subsequently evaluated for recurrence and DSS. The time intervals start at date of initial surgical resection. Cox proportional hazards models were used to determine factors associated with recurrence and DSS.<br />Results: From 1972 to 2010, 76 patients with RP-LPS had at least 10 years of follow-up evaluation. Of these 76 patients, 39 (51%) demonstrated 10yr-PFS. The median follow-up period was 15 years (range 10-33 years). Among the 10yr-PFS patients, 49% (19/39) experienced a recurrence at least 10 years after surgery. Of those who experienced recurrence, 42% (8/19) died of disease. Neither long-term recurrence nor DSS were significantly associated with age, sex, tumor size, LPS subtype, surgical margin, or perioperative treatment with radiation or chemotherapy.<br />Conclusion: Patients who have primary RP-LPS treated with surgical resection ± multimodality therapy face a long-term risk of recurrence and disease-specific death unacknowledged by current surveillance imaging guidelines. Among the patients with 10yr-PFS, 49% experienced a recurrence, and 42% of those died of disease. These findings suggest a need for lifelong surveillance imaging for patients with RP-LPS.<br /> (© 2022. Society of Surgical Oncology.)

Details

Language :
English
ISSN :
1534-4681
Volume :
30
Issue :
5
Database :
MEDLINE
Journal :
Annals of surgical oncology
Publication Type :
Academic Journal
Accession number :
36581724
Full Text :
https://doi.org/10.1245/s10434-022-12977-0